Market Research Report
Cystic Fibrosis - Market Insights, Epidemiology, and Market Forecast - 2030
|Published by||DelveInsight Business Research LLP||Product code||955302|
|Published||Pre-Order||Content info||219 Pages
Delivery time: 10 business days
|Cystic Fibrosis - Market Insights, Epidemiology, and Market Forecast - 2030|
|Published: Pre-Order||Content info: 219 Pages||
DelveInsight's 'Cystic Fibrosis (CF) - Market Insights, Epidemiology, and Market Forecast - 2030' report delivers an in-depth understanding of the Cystic Fibrosis (CF), historical and forecasted epidemiology as well as the market trends in the United States, and EU5 (Germany, Spain, Italy, France, and United Kingdom).
The Cystic Fibrosis (CF) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Cystic Fibrosis (CF) symptoms market size from 2017 to 2030 segmented by six major markets. The report also covers current Cystic Fibrosis (CF) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Cystic Fibrosis (CF) Overview
First identified nearly 80 years ago, cystic fibrosis (CF) is an autosomal recessive genetic disorder that causes damage to the lungs and the digestive system with the highest prevalence in Europe, North America, and Australia. A genetic mutation causes this disease in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The CFTR protein is a chloride-conducting trans-membrane conductance regulator belonging to the ABC transporter class. It helps in the transportation of chloride ions, thereby maintaining the electrochemical gradient as well as osmotic and fluid balance in the passageways.
A defect in CFTR protein due to an autosomal recessive mutation in the gene can have a wide range of debilitating consequences. The most common defect is highly viscous mucus that obstructs airway tracts which leads to difficulty in breathing. Moreover, it serves as a breeding ground for a huge range of bacterial infections like Staphylococcus aureus, Haemophilus influenza, and Pseudomonas aeruginosa. CFTR is present in other parts of the body as well; therefore, other consequences of such a mutation include malabsorption, pancreatic dysfunction, infertility, bowel obstruction, among many others.
Cystic Fibrosis (CF) Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Cystic Fibrosis (CF) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, and Europe.
The DelveInsight Cystic Fibrosis (CF) market report gives a thorough understanding of Cystic Fibrosis (CF) symptoms by including details such as disease definition, symptoms, causes, physiology, and diagnosis. It also provides Cystic Fibrosis (CF) symptoms of treatment algorithms and treatment guidelines for Cystic Fibrosis (CF) symptoms in the US, and Europe.
Earlier diagnostic tools relied on phenotype, with clinical recognition of characteristic signs and symptoms. Advancement in diagnostic capabilities facilitated the adoption of widespread CF newborn screening (NBS), wherein at least 64% of new CF diagnoses in the US were diagnosed in asymptomatic or minimally symptomatic infants. However, universal NBS was implemented in 2010 in the US, and many individuals born before 2010 have not been screened. The research and development over the last few years have contributed to the understanding of phenotypic and genotypic information of CFTR and has contributed to getting a clearer picture of the disease.
There is no cure for cystic fibrosis, but medications and other therapies can ease symptoms, reduce complications, and improve quality of life. Close monitoring and early, aggressive intervention are recommended to slow the progression of CF, which can lead to a longer life.
Medications used to treat patients with cystic fibrosis may include pancreatic enzyme supplements, multivitamins (particularly fat-soluble vitamins), mucolytics, antibiotics (including inhaled, oral, or parenteral), bronchodilators, anti-inflammatory agents, and CFTR potentiators (e.g., ivacaftor) and correctors (e.g., elexacaftor, lumacaftor, tezacaftor).
The FDA has approved TRIKAFTA, SYMDEKO, ORKAMBI and KALYDECO by Vertex Pharmaceuticals for Cystic Fibrosis (CF).
The Cystic Fibrosis (CF) symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every six major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The diagnosed prevalent cases of Cystic Fibrosis (CF) is increasing in 6MM during the study period, i.e. 2017-2030.
The disease epidemiology covered in the report provides historical as well as forecasted Cystic Fibrosis (CF) symptoms epidemiology segmented as the Total Prevalent cases of Cystic Fibrosis (CF), Gender-specific cases of Cystic Fibrosis (CF), Age-specific cases of Cystic Fibrosis (CF), Type-specific cases of Cystic Fibrosis (CF). The report includes the prevalent scenario of Cystic Fibrosis (CF) symptoms in 6MM covering the United States, and EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) from 2017 to 2030.
The epidemiology segment also provides the Cystic Fibrosis (CF) epidemiology data and findings across the United States, and EU5 (Germany, France, Italy, Spain, and the United Kingdom).
The total prevalent cases of Cystic Fibrosis (CF) associated in 6MM countries was 61,306 in 2017.
The drug chapter segment of the Cystic Fibrosis (CF) report encloses the detailed analysis of Cystic Fibrosis (CF) marketed drugs and early-stage (Phase-I, II, III) pipeline drugs. It also helps to understand the Cystic Fibrosis (CF) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Cystic Fibrosis (CF) Emerging Drug
MRT5005: Translate Bio Inc.
MRT5005, a lead program for the lung, is the first clinical-stage mRNA product candidate designed to address the underlying cause of CF by delivering mRNA encoding fully functional CFTR protein to the lung epithelial cells through nebulization. MRT5005 is being developed to treat all patients with CF, regardless of the underlying genetic mutation, including those with limited or no CFTR protein.
VX-121: Vertex Pharmaceuticals
VX-121 is an orally administered CFTR corrector that helps fix and restore the function of defective CFTR protein. The corrected CFTR protein can then translocate to the cell surface where it performs the normal function and helps maintain the right balance of fluid in the airways. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) is a transmembrane protein in epithelial cells that plays a crucial role in ion transport across the cell, especially the transport of chloride and sodium ions.
Products detail in the report…
The Cystic Fibrosis (CF) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Cystic Fibrosis (CF) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Cystic Fibrosis (CF) market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Cystic Fibrosis (CF) market in 6MM is expected to grow in the study period 2017-2030.
Cloning of CF Transmembrane conductance Regulator (CFTR) gene has provided a breakthrough in the understanding of the molecular basis of this disease. There are over 1,800 mutations of CFTR identified thus far, wherein 23 variants account for the majority of CF-causing mutations. The CF-causing mutations of CFTR can be grouped into classes depending on the physiological effect. Some mutations cause little or no protein to be made (Class I and IV), others create a defective protein that does not make it to the cell membrane (Class II), and others cannot be effectively regulated or conduct chloride (Class III and IV).
Classification of the mutations allows the development of specialized drugs to overcome the specific gene mutation. The most common CF mutation, F508del, is primarily considered to be a processing mutation. The F508del mutation removes a single amino acid from the CFTR protein. Without this building block, the CFTR protein cannot stay in the correct 3-D shape. The cell recognizes that the protein is not the right shape and disposes of it.
Approximately 44% of CF patients are homozygous for the F508del mutation (i.e., F508del/F508del), while around 41% are compound heterozygotes (i.e., F508del/other CF causing CFTR mutation), and about 15% have two non-F508del CF-causing CFTR mutations. Patients who are homozygous for F508del are said to have "classic CF." Patients with classic CF tend to be pancreatic insufficient and have more severe lung disease than CF patients with other mutations.
This section includes a glimpse of the Cystic Fibrosis (CF) market in 6MM. The market size of Cystic Fibrosis (CF) in the six major markets was USD 1,940.1 million in 2017.
This section provides the total Cystic Fibrosis (CF) market size and market size by therapies in the United States.
The United States accounts for the largest market size of Cystic Fibrosis (CF) in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain).
The total Cystic Fibrosis (CF) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers Cystic Fibrosis (CF) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs. It also allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Cystic Fibrosis (CF) Pipeline Development Activities
The report provides insights into the therapeutic candidate in Phase I, II and III stage. It also analyses Cystic Fibrosis (CF) key players involved in developing targeted therapeutics.
Major players include Translate Bio, Inc., Proteostasis Therapeutics, Vertex Pharmaceuticals, and others.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Cystic Fibrosis (CF) emerging therapies.
Reimbursement Scenario in Cystic Fibrosis (CF)
Approaching reimbursement, proactively, can have a positive impact both during the early stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Lumacaftor/ivacaftor was approved by the Food and Drug Administration (FDA) as a combination treatment for Cystic Fibrosis (CF) patients who are homozygous for the F508del mutation. Under the base-case, Lumacaftor/ivacaftor resulted in higher QALYs (7.29 vs. 6.84) but at a very high cost (USD 1,778,920.88) compared to usual care (USD 116,155.76) over 10 years. The ICER for base-case and worst-case scenarios were USD 3,655,352/QALY, and USD 8,480,265/QALY gained, respectively. In the base-case, lumacaftor/ivacaftor was cost-effective at a threshold of USD 150,000/QALY-gained when annual drug costs were lower than USD 4,153; the results were not substantially affected by the sensitivity analyses. The intervention produced substantial QALY gains but at an extremely high cost, resulting in an ICER that would not typically be covered by any insurer. Hence, Lumacaftor/ivacaftor's status as an orphan drug complicates coverage decisions.
Although CF is uncommon, it represents a significant economic burden. In 2013, CF-related hospital costs alone were estimated to exceed USD 1.1 billion. Institute for Clinical and Economic Review (ICER) reviewed the Tufts Medical Center Specialty Drug Evidence and Coverage (SPEC) Database for US commercial health plan coverage policies for Trikafta, Kalydeco, Orkambi, Symdeko, developed by the Center for Evaluation of Value and Risk in Health.
To keep up with current market trends, we take KOLs and SME's opinion working in Cystic Fibrosis (CF) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Cystic Fibrosis (CF) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Cystic Fibrosis (CF) Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies: